INSMED INC (INSM)

US4576693075 - Common Stock

20.03  +0.25 (+1.26%)

After market: 20.03 0 (0%)

News Image
a day ago - Insmed Incorporated

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
17 days ago - Market News Video

INSM Crosses Above Key Moving Average Level

News Image
17 days ago - Insmed Incorporated

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW...

News Image
a month ago - Insmed Incorporated

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

—Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025— —Company Reveals Select Initial...

News Image
a month ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
a month ago - Insmed Incorporated

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update

—Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024—...

News Image
2 months ago - Insmed Incorporated

Insmed to Host Investor and Analyst Event on May 8, 2023

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
2 months ago - Insmed Incorporated

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
2 months ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
2 months ago - Insmed Incorporated

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
3 months ago - Insmed Incorporated

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
3 months ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
4 months ago - Insmed Incorporated

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

—Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of...

News Image
5 months ago - Insmed Incorporated

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment...

News Image
5 months ago - Insmed Incorporated

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
6 months ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
6 months ago - Insmed Incorporated

Insmed To Present at the Nasdaq 47th Investor Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image
7 months ago - Market News Video

First Week of INSM January 2023 Options Trading

News Image
7 months ago - Market News Video

Top Buys by Directors: Lee's $796K Bet on INSM

News Image
7 months ago - Insmed Incorporated

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...